Kai Wang

Mr. Kai Wang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
QLQuan xing Liu
Quan xing Liu
LJLi Jiang
Li Jiang
KWKai Wang
Kai Wang
JDJi-Gang Dai
Ji-Gang Dai
XLXiaobing Liu
Xiaobing Liu
Lung cancer remains the leading cause of cancer mortality, hindered by drug resistance, limited targeting, and low immunotherapy response. This review presents biomimetic superparamagnetic iron-oxide nanoparticles (SPIONs) as a next-generation theranostic platform. By cloaking SPIONs with cell membranes—macrophage, neutrophil, or cancer cell—we endow them with biological targeting, immune evasion, and deep lung penetration. Coupled with magnetic field-guided retention and real-time imaging, these systems enable precision hyperthermia, on-demand drug release, and immune microenvironment reprogramming. We critically compare membrane types, outline translational challenges, and propose a regulatory-aligned safety framework. This biomimetic strategy offers a dual diagnostic–therapeutic solution for lung cancer and potentially other solid tumors.

20 August 2026 in Phytomedicine
Verified
Journal Article
Open access
SLSijin Liu
Sijin Liu
CYChengfei Yang
Chengfei Yang
ZHZiqi Huang
Ziqi Huang
MZMenglin Zhou
Menglin Zhou
ZZZhi Zheng
Zhi Zheng
JDJi-Gang Dai
Ji-Gang Dai

1 November 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
KWKai Wang
Kai Wang
XDXu-Feng Deng
Xu-Feng Deng
ZZZhi Zheng
Zhi Zheng
ZHZi-Qi Huang
Zi-Qi Huang
SLShuang-Qing Liao
Shuang-Qing Liao
QLQuan xing Liu
Quan xing Liu
Background: Globally, lung cancer is the most frequently diagnosed malignancy, for which solid pulmonary nodules (SPNs) are a common radiographic finding. Given the high false-positive rates of computed tomography (CT) screening, we aimed to develop a multimodal diagnostic model combining CT radiomics features and serum biomarkers via machine learning. Methods: This retrospective study included patients receiving both preoperative CT screening and serum biomarker testing. All pulmonary nodules (PNs) were divided into training and validation sets randomly at a ratio of 7:3. We developed a multimodal diagnosis model based on the CT radiomics and protein biomarkers of SPNs in the training cohort. The CT radiomics features were derived from the integration of traditional radiomics analysis methods and three-dimensional (3D) deep learning techniques. The accuracy of this multimodal diagnosis model for the prediction of SPNs was verified in the validation set. Model performances were evaluated in terms of the area under the curve (AUC), accuracy, positive predictive value (PPV), negative predictive value (NPV), decision curve analysis (DCA), and calibration curve. Results: Between February 2016 and December 2020, imaging data of 638 eligible PNs from CT scans of 633 different patients were collected. The multimodal model had satisfactory accuracy in differentiating benign and malignant SPNs in the training set [AUC =0.944; 95% confidence interval (CI): 0.924–0.964]. In the validation set, the multimodal model yielded an AUC of 0.926 (95% CI: 0.889–0.964), an accuracy of 0.885, an NPV of 0.812, and a PPV of 0.927. The multimodal model also significantly outperformed the single-modality diagnostic models, including the traditional radiomics CT model (AUC =0.843; 95% CI: 0.780–0.906), the serum biomarker model (AUC =0.783; 95% CI: 0.718–0.847), and the 3D deep learning model (AUC =0.820; 95% CI: 0.754–0.885) (all P values <0.01). Conclusions: This study developed a novel multimodal that demonstrated superior performance in classifying SPNs. It may thus enhance the diagnosis of benign and malignant lesions and provide support for clinical decision-making.